Soligenix
SNGX · NASDAQ
$0.3546+$0.0109 (+3.17%)TodayMarket closed ·
Prev close $0.3437
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 23.9% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.1581 | -$0.12 | +24.1% |
| Q1 FY26 | -$0.2856 | -$0.28 | +2.0% |
| Q4 FY25 | -$0.5712 | -$0.28 | +51.0% |
| Q3 FY25 | -$0.5661 | -$0.58 | −2.5% |
| Q2 FY25 | -$0.9384 | -$0.82 | +12.6% |
| Q1 FY25 | -$0.6834 | -$1.06 | −55.1% |
| Q4 FY24 | -$0.969 | -$1.14 | −17.6% |
| Q3 FY24 | -$1.11 | -$0.78 | +29.8% |
Earnings calls
- Special Call - Soligenix, Inc.
- Special Call - Soligenix, Inc.
- Special Call - Soligenix, Inc.
- Virtual Fall Investor Summit 2020
- Cantor’s 2020 Global Healthcare Conference
- MedInvest Infectious Disease and Immunology Investor Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.